The Irish company Cosmo Pharmaceuticals has evaluated the topical solution clascoterone in two parallel Phase III studies in people with male androgenetic alopecia, the most common form of hair loss, affecting more than 70 percent of all men at some point in their lives.
In both studies, the treatment demonstrated statistically significant and clinically meaningful improvements in hair growth compared with placebo, the company said in a press release.
BREAKING